Dexloxiglumide. CCK1 (CCK(A)) receptor antagonist, treatment of irritable bowel syndrome

Drugs of the Future

Volumn 24, Issue 7, 1999, Pages 725-728

  Revel, Laura ^a   Makovec, Francesco ^b   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

^b Rotta Research Laboratorium   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DEVAZEPIDE; DEXLOXIGLUMIDE; LOXIGLUMIDE;

ARTICLE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG INDICATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IRRITABLE COLON; NONHUMAN; STOMACH EMPTYING;

EID: 0032877766     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.07.482253     Document Type: Article

References (35)

1. Makovec, F., Chiste, R., Peris, W., Rovati, L. (Rotta Res. Lab. SpA). Derivs. of (R)-5-pentylamino-5-oxopentanoic acid with anticholecystokinin activity. EP 344184, JP 88201156, US 5130474, US 5391574, WO 8805774.
2. Crawley, J.E., Corwin, R.L. Biological actions of cholecystokinin. Peptides 1994, 15: 731-55.
3. Ivy, A.C., Oldberg, E.A. Hormone mechanism for gallbladder contraction end evacuation. Am J Physiol 1928, 86: 599-613.
4. Ryan, J.P. Motility of the gallbladder and biliary tree. In: Physiology of the Gastrointestinal Tract. Johnson, L.R. (Ed.). Raven Press: New York 1987, 695-721.
5. Chey, W.Y. Hormonal control of pancreatic exocrine secretion. In: The Pancreas: Biology, Pathobiology and Disease. Go, V.L.W., DiMagno, P., Gardner, J.D., Lebenthal, E., Reber, H.A., Scheele, G.A. (Eds.). Raven Press: New York 1993, 117-41.
6. Niederau, C., Lüthen, R., Heintges, T. Effects of CCK on pancreatic function and morphology. Cholecystokinin 1994, 713: 180-98.
7. Petersen, H., Solomon, T., Grossman, M.I. Effect of pentagastrin, cholecystokinin and secretin on pancreas of rats. Am J Physiol 1978, 234: E286-93.
8. Grider, J.R. Role of cholecystokinin in the regulation of gastrointestinal motility. J. Nutr 1994, 124 (Suppl. 8): 1334S-9S.
9. Scarpignato, C., Varga, G., Corradi, C. Effect of CCK and its antagonists on gastric emptying. J Physiol (Paris) 1993, 87:291-300.
10. Fossati-Marchal, S., Coffin, B., Flourié, B. et al. Effects of cholecystokinin octapeptide (CCK-OP) on the tonic and phasic motor activity on the human colon. Gastroenterology 1994, 106: A499.
11. Lederboer, M., Masclee, A.A.M., Batstra, M.R., Jansen J.B.M., Lamers, C.B.H. Effects of cholecystokinin on lower esophageal sphincter pressure and transient lower esophageal sphincter relaxation in humans. Gut 1995, 36: 39-44.
12. Innis, R.B., Snyder, S.H. Distinct cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci USA 1980, 77: 6917-28.
13. Roques, B.P., Noble, F. Cholecystokinin receptors. The IUPHAR Receptor Compendium 1999, 128-33.
14. Bitar, K.N., Makhlouf, G.M. Regional and cellular heterogeneity of cholecystokinin receptors mediating muscle contraction in the gut. Gastroenterology 1987, 92: 175-80.
15. Corp, E., McQuade, S., Moran, T.H., Smith, G.P. Characterization of type A and type B CCK receptor binding sites in rat vagus nerve. Brain Res 1993, 623: 161-6.
16. Beinfeld, M.C. Cholecystokinin in the central nervous system. Neuropeptides 1983, 3: 411-9.
17. Setnikar, I., Bani, M., Cereda, R. et al. Pharmacological characterisation of a new potent and specific nonpolypeptidic cholecystokinin antagonist. Arzneim-Forsch 1987, 37: 703-7.
18. D'Amato, M., Makovec, F., Rovati, L.C. CCKA receptors in gastrointestinal disorders. New therapeutic implications. In: Drug Development: Molecular Targets for Gastrointestinal Diseases. Gaginella, T.S., Guglietta, A. (Eds.), Humana Press, Inc.: Ottowa 1999, 6: 147-76.
19. Varga, G., Kisfalvi, K., D'Amato, M., Scarpignato, C. Effect of a new CCK-A receptor antagonist, dexloxiglumide, on the exocrine pancreas in the rat. J Physiol (Paris) 1997, 91: 257-64.
20. Varga, G., Kisfalvi, K., Pelosini, I., D'Amato, M., Scarpignato, C. Different actions of CCK on pancreatic and gastric growth in the rat: Effect of CCKA receptor blockade. Br J Pharmacol 1998, 124: 435-40.
21. Grider, J.R., Makhlouf, G.M. Distinct receptors for cholecystokinin and gastrin on muscle cells of stomach and gallbladder. Am J Physiol 1990, 259: G184-90.
22. Scarpignato, C., Kisfalvi, I., D'Amato, M., Vargas, G. Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: Evaluation of their receptor selectivity in vivo. Aliment Pharmacol Ther 1996, 10: 411-9.
23. Fioramonti, J., D'Amato, M., Rovati, L., Bueno, L. Effect of dexloxiglumide on gastric emptying delayed by colonic distension in dogs. Neurogastroenterol Motil 1996, 8: 172.
24. Resin, H., Stern, D.H., Sturdevant, R.A.L., Isenberg, J.I. Effect of the C-terminal octapeptide of cholecystokinin on lower oesophageal sphincter pressure in man. Gastroenterology 1973, 64: 946-9.
25. Rouzade, M.L., Fioramonti, J., D'Amato, M., Rovati, L., Bueno, L. Inhibitory action of dexloxiglumide on transient lower oesophageal sphincter relaxation in dogs. Neurogastroenterol Motil 1996, 8: 138.
26. Meier, R., Beglinger, C., Giacovelli, G., D'Amato, M. Effect of the CCK-A receptor antagonist dexloxiglumide on postprandial gallbladder emptying and colonic transit time in healthy volunteers. Gastroenterology 1997, 112 (4, Suppl.): A788.
27. Feinle, C., Meier, O., D'Amato, M., Fried, M. CCK-A receptor blockade improves dyspeptic symptoms due to duodenal lipid and gastric distension in functional dyspepsia. Dig Dis Week (May 16-19, Orlando) 1999, Abst 3932.
28. D'Amato, M., Whorwell, P.J., Thompson, D.G., Spiller, R.C. The CCKA receptor-antagonist dexloxiglumide in the treatment of IBS. Dig Dis Week (May 16-19, Orlando) 1999, Abst 1249.
29. Revel, L., Mennuni, L., Garofalo, P., Makovec, F. CP 2945: A novel CCKB receptor antagonist with anxiolytic-like activity. Behav Pharmacol 1998, 9: 183-94.
30. Fukamizu, Y., Nakajima, T., Kimura, K., Kanda, H., Fujii, M., Saito, T., Kasai, H. Biochemical and pharmacological profiles of loxiglumide, a novel cholecystokinin A receptor antagonist. Arzneim-Forsch Drug Res 1998, 48: 58.
31. Akiyama, T., Tachibana, I., Hirohata, Y., Shirohara, H., Yamamoto, M., Otsuki, M. Pharmacological profile of TP-680, a new CCK-A receptor antagonist. Br J Pharmacol 1996, 117: 1558-64.
32. Horwell, D.C., Hughes, J., Hunter, J.C., Pritchard, M.C., Richardson, R.S., Roberts, E., Woodruff, G.N. Rationally designed "dipeptoid" analogues of CCK. α-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic-like activity. J Med Chem 1991, 34: 404-14.
33. Tachibana, I., Kanagawa, K., Yamamoto, Y. et al. Pharmacological profile of a new serine derivative cholecystokinin receptor antagonist TP-680 on pancreatic, biliary and gastric function. J Pharmacol Exp Ther 1996, 279: 1404-12.
34. Rovati, L.C., Bani, M., Makovec, F., Revel, L., Setnikar, I. Lorglumide and loxiglumide: Two potent and specific antagonists of peripheral CCK. In: Gastrin and Cholecystokinin. Bali, J.P., Martinez, J. (Eds.). Elsevier Science Publishers: New York 1987, 45-8.
35. Lotti, V.J., Pendleton, R.G., Gould, R.J., Hanson, H.M., Chang, R.S., Clineschmidt, B.V. In vivo pharmacology of L-364,718, a new potent nonpeptide peripheral cholecystokinin antagonist. J Pharmacol Exp Ther 1987, 241: 103-9.